Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

FENG Bing; GAO Ning; GAO Shengnan; GUO Shan; NIU Mengna; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2024.08.12

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

更新时间：2025-09-25

- Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- ZHONGGUO YAOFANG Vol. 35, Issue 8, Pages: 967-971(2024)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.08.12
  CLC： R956;R735
- Received：30 October 2023，
  
  Revised：2024-03-21，
  
  Accepted：22 March 2024，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
冯冰,高宁,高胜男,等.替雷利珠单抗联合化疗一线治疗局部晚期不可切除或转移性胃或胃食管结合部腺癌的成本-效果分析[J].中国药房,2024,35(08):967-971.

FENG Bing,GAO Ning,GAO Shengnan,et al.Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma[J].ZHONGGUO YAOFANG,2024,35(08):967-971.
冯冰,高宁,高胜男,等.替雷利珠单抗联合化疗一线治疗局部晚期不可切除或转移性胃或胃食管结合部腺癌的成本-效果分析[J].中国药房,2024,35(08):967-971. DOI： 10.6039/j.issn.1001-0408.2024.08.12.

FENG Bing,GAO Ning,GAO Shengnan,et al.Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma[J].ZHONGGUO YAOFANG,2024,35(08):967-971. DOI： 10.6039/j.issn.1001-0408.2024.08.12.

摘要

目的

评价替雷利珠单抗联合化疗一线治疗局部晚期不可切除或转移性胃或胃食管结合部腺癌的经济性。

方法

从我国卫生体系角度出发，利用RATIONALE-305试验和相关文献数据建立分区生存模型，循环周期为3周，模拟时限为10年，贴现率为5%。以质量调整生命年（QALYs）为健康产出指标，评价替雷利珠单抗联合化疗对比安慰剂联合化疗一线治疗局部晚期不可切除或转移性胃或胃食管结合部腺癌的经济性，并进行单因素敏感性分析和概率敏感性分析。

结果

基础分析结果显示，与安慰剂联合化疗相比，替雷利珠单抗联合化疗方案可使患者多获得0.268 QALYs，但治疗成本会增加70 404.81元，增量成本-效果比（ICER）为262 431.62元/QALY，低于3倍2023年我国人均国内生产总值（GDP）的意愿支付阈值（268 074元/QALY）。单因素敏感性分析结果显示，无进展生存效用值和替雷利珠单抗药品成本对ICER值的影响较大。概率敏感性分析结果显示，当WTP阈值为3倍2023年我国人均GDP时，替雷利珠单抗具有经济性的概率为53.3%。

结论

当WTP阈值为3倍2023年我国人均GDP时，与安慰剂联合化疗方案相比，替雷利珠单抗联合化疗一线治疗局部晚期不可切除或转移性胃或胃食管结合部腺癌具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

METHODS

The data of RATIONALE-305 study and related literature were used to establish a partitioned survival model from the perspective of China’s health system. The cycle was 3 weeks， the simulation time was set as 10 years， and the discount rate was 5%. The quality-adjusted life years （QALYs） were used as the health outcome indicator to evaluate the cost-effectiveness of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma， and one-way sensitivity analysis and probabilistic sensitivity analysis were also conducted.

RESULTS

The base analysis showed that the patients received more 0.268 QALYs with tislelizumab plus chemotherapy， compared with placebo plus chemotherapy， but the cost increased by 70 404.81 yuan with an incremental cost-effectiveness ratio （ICER） of 262 431.62 yuan/QALY， which was less than three times China’s gross domestic product （GDP） per capita in 2023 as the willingness-to-pay （WTP） threshold （268 074 yuan/QALY）. One-way sensitivity analysis showed that the efficacy value of progress free survive and the price of tislelizumab had a greater impact on the ICER value. The results of probability sensitivity analysis showed that when the WTP threshold was 3 times China’s GDP per capita in 2023， the probability of tislelizumab being cost-effective was 53.3%.

CONCLUSIONS

When the WTP threshold is 3 times China’s GDP per capita in 2023， tislelizumab plus chemotherapy is cost-effective for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma， compared with placebo plus chemotherapy.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

GUO X J ， ZHAO F X ， MA X F ， et al . A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer：a systematic review and meta-analysis [J ] . BMC Cancer ， 2019 ， 19 （ 1 ）： 1125 .

VAN CUTSEM E ， SAGAERT X ， TOPAL B ， et al . Gastric cancer [J ] . Lancet ， 2016 ， 388 （ 10060 ）： 2654 - 2664 .

国家卫生健康委员会医政医管局 . 胃癌诊疗指南：2022年版 [J ] . 中华消化外科杂志， 2022 ， 21 （ 9 ）： 1137 - 1164 .

Medical Administration Bureau of National Health Commission . Standardization for diagnosis and treatment of gastric cancer，2022 edition [J ] . Chin J Dig Surg ， 2022 ， 21 （ 9 ）： 1137 - 1164 .

KOLE C ， CHARALAMPAKIS N ， TSAKATIKAS S ， et al . Immunotherapy for gastric cancer：a 2021 update [J ] . Immunotherapy ， 2022 ， 14 （ 1 ）： 41 - 64 .

姜志超，周爱萍 . 晚期胃癌一线免疫治疗的现状与进展 [J ] . 中国肿瘤临床， 2023 ， 50 （ 4 ）： 206 - 211 .

JIANG Z C ， ZHOU A P . Current status and progress of first-line immunotherapy for advanced gastric cancer [J ] . Chin J Clin Oncol ， 2023 ， 50 （ 4 ）： 206 - 211 .

GALLUZZI L ， HUMEAU J ， BUQUÉ A ， et al . Immuno-stimulation with chemotherapy in the era of immune checkpoint inhibitors [J ] . Nat Rev Clin Oncol ， 2020 ， 17 （ 12 ）： 725 - 741 .

XU R H ， OH D Y ， KATO K ， et al . LBA80 tislelizumab（TIS）plus chemotherapy（Chemo）vs placebo（PBO）plus chemo as first-line（1L）treatment of advanced gastric or gastroesophageal junction adenocarcinoma（GC/GEJC）：final analysis results of the RATIONALE-305 study [J ] . Ann Oncol ， 2023 ， 34 （ Suppl.2 ）： S1320 - S1321 .

周颖玉，吴群红 . 经济学理论视角下的健康贴现率研究 [J ] . 中国卫生经济， 2023 ， 42 （ 1 ）： 1 - 3 .

ZHOU Y Y ， WU Q H . Further discussion on health discount rate from the perspective of economic theory [J ] . Chin Health Econ ， 2023 ， 42 （ 1 ）： 1 - 3 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

SHI F H ， SHANG Y ， RUI M J ， et al . Application of survHE package of R for health economic evaluation [J ] . Chin Health Econ ， 2020 ， 39 （ 9 ）： 9 - 14 .

LU S J ， LOU Y K ， RONG Y ， et al . Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for Chinese patients with advanced esophageal squamous cell carcinoma：a cost-effectiveness analysis [J ] . Clin Drug Investig ， 2023 ， 43 （ 8 ）： 643 - 652 .

SHU Y M ， DING Y F ， ZHANG Q L . Cost-effectiveness of nivolumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma in China [J ] . Front Oncol ， 2022 ， 12 ： 851522 .

WU B ， LI T ， CAI J ， et al . Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy [J ] . BMC Cancer ， 2014 ， 14 ： 984 .

HE J P ， WEN F ， YIN X D ， et al . Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer [J ] . Anticancer Drugs ， 2013 ， 24 （ 7 ）： 754 - 758 .

QIAO L ， ZHOU Z ， ZENG X H ， et al . Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non-small-cell lung cancer in China [J ] . Front Pharmacol ， 2021 ， 12 ： 728440 .

SHIROIWA T ， FUKUDA T ， SHIMOZUMA K . Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial [J ] . Br J Cancer ， 2011 ， 105 （ 9 ）： 1273 - 1278 .

LANG Y T ， LIN Y ， LI D ， et al . Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer：a cost-effectiveness analysis [J ] . Cancer Med ， 2023 ， 12 （ 18 ）： 18447 - 18459 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer

Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Related Author

LIU Guoqiang

GAO Ning

FENG Bing

GAO Shengnan

ZHANG Yuxi

ZHANG Ranran

WANG Xianying

LIANG Miao

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital

Key Laboratory of Correlation Technology of Pharmaceutical Preparations In Vitro and In Vivo， National Medical Products Administration

Evidence-based Medicine Center， West China Hospital， Sichuan University

Molecular Translational Medicine Laboratory， Translational Medicine Center， Sichuan University

Dept. of Pediatrics， West China Second Hospital， Sichuan University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰